All In Biotech

Drug Trial Radar · NCT07629583

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Nov 2, 2026

Primary completion

Mar 29, 2030

Study completion Mar 29, 2030

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • CevostamabDrug

    Participants will receive cevostamab IV as per the schedule given in the protocol.

  • TocilizumabDrug

    Tocilizumab may be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Adverse Events (AEs)Time frame: Up to approximately 52 weeks

Locations

11 sites in 6 countries. Site status is shown where the registry gives one.

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia · Recruiting

  • Hospital Moinhos de Vento

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital de Clnicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital das Clínicas FMRP-USP

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto

    Sao Jose Rio Preto, São Paulo, Brazil · Recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China · Recruiting

  • Hopital Rangueil

    Toulouse, Haute Garonne, France · Recruiting

  • Istituto Clinico Humanitas

    Rozzano, Lombardy, Italy · Recruiting

  • Hospital Universitario Virgen Macarena

    Seville, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.